Srinagar Magazine

Alzheimer’s Disease Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

 Breaking News
  • No posts were found

Alzheimer’s Disease Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

March 13
20:52 2023
Alzheimer’s Disease Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

DelveInsight’s, “Alzheimer’s Disease Pipeline Insights, 2023,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease pipeline landscape. It covers the Alzheimer’s disease pipeline drug profiles, including Alzheimer’s Disease clinical trials and nonclinical stage products. It also covers the Alzheimer’s disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Alzheimer’s Disease Emerging drugs, the Alzheimer’s Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Alzheimer’s Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Alzheimer’s Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Alzheimer’s Disease clinical trials studies, Alzheimer’s Disease NDA approvals (if any), and product development activities comprising the technology, Alzheimer’s Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Alzheimer’s Disease Pipeline Report

 

  • DelveInsight’s Alzheimer’s disease pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Alzheimer’s disease treatment.

 

  • The leading Alzheimer’s disease Companies includes Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,  Otsuka Pharmaceutical Co., Ltd.,  Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,  Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics Inc, and others.

 

  • Promising Alzheimer’s disease Pipeline Therapies includes ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002, CMS121,  LX1001,  TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx,   Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916,  AR1001, ORY-2001, LY3372689, MW150,  EX039, SLS-005,  Seltorexant, Donanemab,  SHR-1707, REM0046127,  ALZ-101, VT301, NE3107, PRX005, MK-6240,  and others.

 

  • Alzheimer’s Disease Companies and academics are working to assess challenges and seek opportunities that could influence Pheochromocytoma R&D. The Alzheimer’s Disease pipeline therapies under development are focused on novel approaches to treat/improve Alzheimer’s Disease.

  

Request a sample and discover the recent breakthroughs happening in the Alzheimer’s Disease Pipeline landscape @ Alzheimer’s Disease Pipeline Outlook Report

 

Alzheimer’s Disease Overview

Alzheimer’s Disease (AD) is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer’s disease are the accumulation of the protein fragment beta‐amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.

 

Recent Developmental Activities in the Alzheimer’s Disease Treatment Landscape

 

  • In February 2023, Lantheus Holdings, Inc. announced it had acquired Knoxville-based Cerveau Technologies, Inc. (“Cerveau”). Cerveau’s asset is MK-6240, a second-generation F 18-labeled positron emission tomography (“PET”) imaging agent that targets Tau tangles in Alzheimer’s disease.Under the terms of the agreement, Lantheus will pay an upfront payment and potential additional development and commercial milestone payments. Additionally, Lantheus will pay double-digit royalty payments for research revenue and commercial sales.

 

  • In January 2023, Prothena Corporation plc announced positive topline Phase I single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer’s disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms. The results of the study found all three dose level cohorts of PRX005 to be generally safe and well tolerated, meeting the Phase 1 SAD study primary objective. None of the treatment emergent adverse events (TEAE) were serious. No clinically relevant changes were observed in other safety parameters. PRX005 also met key pharmacokinetic (PK) and immunogenicity secondary endpoints.

 

  • In January 2023, Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the accelerated approval submission of donanemab for the treatment of early symptomatic Alzheimer’s disease due to the limited number of patients with at least 12 months of drug exposure data provided in the submission. No other deficiencies in the application were noted.The confirmatory Phase 3 TRAILBLAZER-ALZ 2 trial remains ongoing, with topline data read-out expected in Q2 2023, and will form the basis of donanemab’s application for traditional approval shortly thereafter. Lilly will continue to work with the FDA to evaluate the fastest pathway to make this potential treatment option widely available to patients.

 

  • In January 2023, Coya Therapeutics, Inc. announced the recent publication of an article entitled “Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s Disease” in the peer-reviewed journal Acta Neuropathologica Communications.Furthermore, Treg-treated mice showed a significant reduction in total and plaque-associated microglia as well as reactive astrocytes in the dentate gyrus and frontal cortex versus untreated mice. The reduction in the number of plaque-associated glial cells and suppression of pro-inflammatory signaling pathways within these cells following Treg therapy may attenuate the contribution of these toxic glial cells in AD pathology resulting in mitigation of amyloid burden.

 

  • In November 2022, Eli Lilly and Company announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase III TRAILBLAZER-ALZ 4 study, providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer’s disease treated with amyloid-targeting therapies. Donanemab is an investigational antibody that targets a modified form of beta-amyloid plaque called N3pG.

 

For further information, refer to the detailed Alzheimer’s Disease Drugs Launch, Alzheimer’s Disease Developmental Activities, and Alzheimer’s Disease News, click here for Alzheimer’s Disease Ongoing Clinical Trial Analysis

 

Alzheimer’s Disease Emerging Drugs Profile

  • BAN2401: Eisai

BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils. BAN2401 selectively binds to neutralize and eliminate toxic Aβ protofibrils that are thought to be a causative factor for Alzheimer’s Disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007.

 

  • Gantenerumab: Hoffmann-La Roche

Gantenerumab is an investigational therapy designed to bind more specifically to aggregated forms of beta-amyloid and remove beta-amyloid plaques. Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. This treatment is administered as an injection under the skin, is now being developed by Hoffmann-La Roche in collaboration with MorphoSys.

 

Alzheimer’s Disease Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Alzheimer’s Disease (AD). The companies which have their Alzheimer’s Disease (AD) drug candidates in the most advanced stage, i.e. phase III include, Eisai.

 

Find out more about the Alzheimer’s Disease Pipeline Segmentation, Therapeutics Assessment, and Alzheimer’s Disease Emerging Drugs @ Alzheimer’s Disease Treatment Landscape

 

Scope of the Alzheimer’s Disease Pipeline Report

 

  • Coverage- Global

 

  • Alzheimer’s Disease Companies- Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,  Otsuka Pharmaceutical Co., Ltd.,  Cognition Therapeutics, Merck Sharp & Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,  Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research & Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics Inc, and others

 

  • Alzheimer’s Disease Pipeline Therapies- ALZT-OP1, Tricaprilin, Bryostatin-1, INB03, Sumifilam, Neflamapimod, Pegylated exenatide, NLY-02, Masitinib, Atuzaginstat, COR588, Blarcamesine, NDX-1017, Bromocriptine, DNL788, AL002, CMS121,  LX1001,  TB006, Pepinemab, Posiphen, E2814, RO7126209, IONIS MAPTRx,   Brexpiprazole, CT1812, MK-1942, IBC Ab002, ABBV-916,  AR1001, ORY-2001, LY3372689, MW150,  EX039, SLS-005,  Seltorexant, Donanemab,  SHR-1707, REM0046127,  ALZ-101, VT301, NE3107, PRX005, MK-6240, and others.

 

  • Alzheimer’s Disease Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Alzheimer’s Disease Pipeline Companies and Therapies, click here @ Alzheimer’s Disease Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Alzheimer’s Disease (AD): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Alzheimer’s Disease (AD) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Alzheimer’s Disease (AD) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. BAN2401: Eisai
  11. Mid Stage Products (Phase II)
  12. Bryostatin-1: Neurotrope
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. INB03 – INmune Bio
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. AZT-211: AZTherapies
  19. Drug profiles in the detailed report…..
  20. Inactive Products
  21. Alzheimer’s Disease (AD) Key Companies
  22. Alzheimer’s Disease (AD) Key Products
  23. Alzheimer’s Disease (AD)- Unmet Needs
  24. Alzheimer’s Disease (AD)- Market Drivers and Barriers
  25. Alzheimer’s Disease (AD)- Future Perspectives and Conclusion
  26. Alzheimer’s Disease (AD) Analyst Views
  27. Alzheimer’s Disease (AD) Key Companies
  28. 28.   Appendix

 

Got Queries? Find out the related information on Alzheimer’s Disease Mergers and acquisitions, Alzheimer’s Disease Licensing Activities @ Alzheimer’s Disease Recent Trends, and Future Perspectives  

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/